|
WO2021079300A1
|
|
Compositions for preventing or treating chronic obstructive pulmonary diseases (copd)
|
|
KR102227100B1
|
|
Donepezil ether palmitate or its pharmaceutically acceptable salt
|
|
WO2021020771A1
|
|
Stable pharmaceutical composition comprising esomeprazole and sodium bicarbonate
|
|
WO2020240493A1
|
|
1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
|
|
KR20200138086A
|
|
1,3,4-Oxadiazole Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same
|
|
KR20210012881A
|
|
Pharmaceutical formulation comprising esomeprazole and sodium bicarbonate having improved drug release properties
|
|
KR20200018527A
|
|
Stable pharmaceutical composition comprising esomeprazole and sodium bicarbonate
|
|
KR20200077436A
|
|
Fusion Protein Comprising Human Lefty A Protein Variants And Use Thereof
|
|
KR20200074037A
|
|
Composition comprising dutasteride
|
|
KR20200061310A
|
|
Pharmaceutical composition comprising histone deacetylase 6 inhibitors
|
|
WO2020080806A1
|
|
Injectable long-acting naltrexone microparticle compositions
|
|
WO2020076129A1
|
|
Pharmaceutical composition comprising histone deacetylase inhibitor and methotrexate
|
|
KR20210030109A
|
|
Method for the Preparation of Diamine Derivative
|
|
KR20200023185A
|
|
Pharmaceutical formulation comprising esomeprazole and sodium bicarbonate having improved drug release properties
|
|
KR102051808B1
|
|
Stable pharmaceutical composition comprising testosterone undecanoate
|
|
KR101980534B1
|
|
Donepezil myristyloxymethyl ether or its pharmaceutically acceptable salt
|
|
KR20200012316A
|
|
1,3,4-Oxadiazole Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same
|
|
KR20190012118A
|
|
Composition for preventing or treating cancer comprising a vascular disrupting agent and immune checkpoint inhibitor
|
|
KR20200000038A
|
|
Sustained release pharmaceutical preparation comprising tacrolimus
|
|
KR20190138537A
|
|
Controlled release pharmaceutical formulation comprising Lobeglitazone and Metformin
|
